Men's Hormone Optimization in 2026: A Factual Look at Testosterone, the TRAVERSE Trial, and the Current Clinical Standard

Posting this for anyone researching low testosterone, TRT, or men's hormone optimization. The clinical picture has changed substantially in the past three years, and a lot of the older information online is now out of date.

The Basic Biology

Testosterone production declines with age, roughly 1 to 2 percent per year after age 30. This is well-documented in longitudinal studies including the Baltimore Longitudinal Study of Aging and the European Male Aging Study.

For most men, this decline is gradual and the symptoms accumulate slowly. By the time many men actually evaluate their levels, they've been operating below their personal baseline for years.

Common symptoms associated with clinically low testosterone include persistent fatigue, reduced muscle mass and strength, increased body fat (especially abdominal), reduced libido and erectile changes, low mood and reduced motivation, cognitive symptoms (brain fog, focus issues), sleep disruption, and slower exercise recovery. The European Male Aging Study established the three sexual symptoms — reduced morning erections, reduced libido, and erectile dysfunction — as the most strongly correlated with biochemically confirmed low testosterone.

The TRAVERSE Trial Changed the Conversation

Most of the cautious framing around testosterone replacement came from a 2010 study (Basaria et al.) and a 2013 retrospective analysis that raised cardiovascular safety concerns. Those concerns shaped clinical practice for over a decade.

The TRAVERSE trial, published in The New England Journal of Medicine in June 2023, was designed specifically to resolve the cardiovascular safety question. The trial enrolled 5,246 men aged 45 to 80 with documented hypogonadism (two morning testosterone levels below 300 ng/dL) and either established cardiovascular disease or high cardiovascular risk. Participants were randomized to testosterone gel or placebo and followed for an average of 21.7 months.

The primary endpoint was the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.

Results: testosterone replacement did not increase the risk of major adverse cardiovascular events compared to placebo (7.0% vs 7.3%; hazard ratio 0.96; 95% CI 0.78 to 1.17; p<0.001 for noninferiority).

This is the largest, longest, placebo-controlled trial of testosterone replacement in men with documented hypogonadism and cardiovascular risk factors that has ever been conducted. The clinical implications are significant: cardiovascular risk concerns can no longer be used as a blanket contraindication for testosterone replacement in symptomatic, biochemically confirmed hypogonadism.

There were some adverse findings worth knowing. Testosterone-treated patients had higher rates of atrial fibrillation (3.5% vs 2.4%), acute kidney injury (2.3% vs 1.5%), and pulmonary embolism (0.9% vs 0.5%). The trial's authors flagged these as warranting continued monitoring and patient discussion.

The Diagnostic Standard

The Endocrine Society Clinical Practice Guideline (updated 2018) requires both clinical symptoms consistent with low testosterone and biochemically confirmed low total testosterone on at least two separate morning blood draws before initiating treatment.

A single low reading is insufficient. Testosterone levels fluctuate naturally based on time of day, sleep, stress, recent illness, and other factors. Morning draws are required because testosterone follows a circadian rhythm that peaks in the early morning and declines through the day.

The reference range typically used is 264 to 916 ng/dL based on the CDC harmonization standard. The cutoff used in clinical trials varies, with TRAVERSE using <300 ng/dL on two separate draws as the entry criterion.

A thorough workup also includes free testosterone, SHBG (sex hormone-binding globulin), LH and FSH, estradiol, thyroid function, prolactin, complete blood count, lipid panel, PSA in age-appropriate patients, and assessment of metabolic markers. Some men have normal total testosterone but elevated SHBG, which can result in clinically low free testosterone despite an apparently normal panel.

What the Evidence Supports

The established benefits of testosterone replacement in men with documented hypogonadism are reasonably well-characterized.

A 2017 meta-analysis in The Journal of Clinical Endocrinology and Metabolism found significant improvements in sexual function across multiple domains. The TTrials (Testosterone Trials), a coordinated series of seven trials in older men, demonstrated improvements in sexual activity, mood, depressive symptoms, walking distance, and hemoglobin levels.

Body composition effects are consistent across studies: increases in lean mass averaging 1 to 3 kg and decreases in fat mass of similar magnitude over 6 to 12 months of treatment. Bone mineral density improvements are documented in longer-duration studies. Improvements in mood and depressive symptoms are documented but more modest than the body composition and sexual function effects.

The effects are most pronounced in men whose pretreatment levels are clearly low and whose symptoms align with the diagnosis. Men with borderline levels and ambiguous symptoms tend to see more variable results.

The Monitoring Requirements

Testosterone replacement requires ongoing clinical monitoring. The standard cadence involves baseline labs, repeat labs at 3 and 6 months after initiation or dose change, and then every 6 to 12 months once stable.

Markers that require monitoring include testosterone (total and free), hematocrit (testosterone can increase red blood cell production, occasionally to levels requiring treatment pause or dose reduction), PSA in age-appropriate patients, estradiol (some testosterone aromatizes to estradiol; significantly elevated levels can require management), and lipid panel.

Patients are typically advised to be aware of and report sleep apnea symptoms, lower extremity swelling, mood changes, and other clinically relevant changes.

Treatment Options

Several routes are clinically established. Injectable testosterone (typically cypionate or enanthate) administered intramuscularly or subcutaneously is widely used and offers dose flexibility. Testosterone gel applied daily provides steady-state levels but requires careful handling to prevent transfer to others. Subcutaneous testosterone pellets provide sustained release over months with less frequent dosing. HCG can be used to preserve endogenous testicular function, often combined with TRT in men prioritizing fertility preservation.

No single route is superior for all patients. Selection is typically based on patient preference, dosing flexibility needs, lifestyle factors, and clinical response.

The Regulatory Context

In Nevada, APRNs with FNP-C credentials can independently evaluate, prescribe, and manage testosterone replacement therapy without referral requirements. This regulatory framework has expanded access to clinically supervised hormone care across the state, including in markets where physician access has historically been limited.

The trade-off worth understanding: APRN-led hormone clinics range from rigorous, lab-driven, well-monitored practices to high-volume operations focused on rapid prescription. The credentials of the provider matter, but so does the clinical structure of the practice — diagnostic depth, monitoring cadence, and willingness to adjust or discontinue treatment when clinically indicated.

What to Look For

If you're researching providers, the markers of a clinically rigorous practice include: a complete diagnostic workup before treatment, not just a single testosterone reading; explicit discussion of the TRAVERSE findings and any individual risk factors; a clear monitoring schedule communicated up front; willingness to discuss what would prompt dose adjustments or treatment pause; and integration with related care (sleep evaluation, metabolic assessment, cardiovascular risk) rather than treating testosterone as an isolated number.

Practices that prescribe based on single low readings, skip the comprehensive panel, or don't outline a monitoring plan are not operating at the current clinical standard regardless of how the marketing reads.

The Bottom Line

Men's hormone optimization in 2026 is a more evidence-based field than it was even three years ago. The TRAVERSE trial resolved much of the cardiovascular safety question. The diagnostic standards are well-established. The treatment options are flexible. The monitoring requirements are clear.

The remaining variable, for most men, is finding a provider who applies the clinical standard rigorously rather than transactionally.

More information: https://reignbeautyvitality.com